This led to the development of samalizumab (ALXN6000), a first-in-class anti-CD200 antibody tested in phase I clinical trials for multiple myeloma and chronic lymphocytic leukaemia by Alexion Pharmaceuticals [48]. The gene discussed is CD200; the disease is AL amyloidosis.